Study of encaleret in children with a rare calcium disorder
Part of Hormones & metabolism clinical trials.
This trial tests a medicine called encaleret in children with a rare genetic condition that causes low calcium levels. The goal is to see if it safely helps control calcium and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed genetic change in the calcium-sensing receptor (CASR) that causes low calcium or low parathyroid hormone (PTH).
- You must have at least one symptom or sign of hypoparathyroidism (low calcium).
- You must have been on treatment for this condition for at least 3 to 6 months before joining.
- You must not have had thyroid or parathyroid surgery.
- You must not have had a kidney transplant.
- You cannot take certain heart medicines or strong interacting drugs for a period before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows adults with hypoparathyroidism to better understand what symptoms and lab levels change over time. It may help doctors plan future treatments by learning the natural course of the condition, even if you already take standard medicines.
This study tests a new medicine called encaleret for people with chronic hypoparathyroidism, a condition where the body has too little parathyroid hormone, leading to low calcium levels. The medicine aims to improve calcium balance and reduce the need for daily calcium and vitamin D supplements.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
This trial studies etelcalcetide in children who have chronic kidney disease and too much parathyroid hormone while on hemodialysis. It aims to safely lower the hormone levels and help manage related bone/mineral problems.
This Phase 3 trial tests etelcalcetide to lower a hormone called parathyroid hormone (PTH) in children who have kidney disease and secondary hyperparathyroidism while on hemodialysis. It may help control bone/mineral problems, but the study also checks heart rhythm safety and medication stability.
This trial tests a new treatment to help people with hypoparathyroidism (a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels) manage their calcium better. It aims to reduce the need for calcium and vitamin D supplements.
Hear when a new Autosomal Dominant Hypocalcemia Type 1 (ADH1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.